B

Bruker

Manufactures analytical instruments for NMR diagnostics

Solution Portfolio Manager

Full-TimeUpdated on 10/15/2026Deadline 8/4/27
No salary listed
Senior, Expert
Master's, MBA
Beijing, China+1 moreMore locations: Shanghai, China
In Person
ProductProduct Management

About the job

Requirements
  • A Master's degree or PhD in Business, Engineering, Natural Sciences, or a related field is required; exposure to analytical instrumentation, life sciences, or industrial technologies is ideal.
  • Eight to twelve or more years of experience in portfolio management, product management, or solution management.
  • A proven track record managing complex solution portfolios spanning hardware, software, and services; driving portfolio profitability and growth; and delivering end-to-end lifecycle management from concept through launch, optimisation, and phase-out.
  • Experience in cross-regional or global roles, with exposure to different market dynamics.
  • Ability to define, execute, and optimise portfolio roadmaps across lifecycle stages while balancing innovation, performance, and resource allocation.
  • Strong ownership of profit and loss, business case development, pricing strategies, and recurring revenue models.
  • Capability to design and manage integrated solutions combining hardware, software, and services, with a focus on end-to-end customer workflows.
  • Expertise translating market trends, competitive insights, and customer needs into actionable portfolio strategies and value propositions.
  • Ability to align and influence R&D, Product Management, Sales, Marketing, and Service teams in a matrix organisation.
  • Strong skills defining positioning and value propositions and executing global go-to-market strategies, including sales enablement.
  • Ability to operate in matrix organisations and complex environments.
Responsibilities
  • Develop and maintain a comprehensive portfolio roadmap aligned with company strategy and market trends.
  • Monitor solution performance and profitability throughout the lifecycle, from concept to end-of-life, and identify opportunities for portfolio expansion, consolidation, or optimisation using data-driven insights.
  • Define key performance indicators and track portfolio performance, including revenue, margin, and market share.
  • Develop business cases for new investments and ensure resource allocation aligns with strategic priorities.
  • Support pricing strategy, product bundling, and value-based selling initiatives.
  • Drive development of integrated solutions combining hardware, software, and services; promote cross-portfolio synergies and interoperability; and foster innovation with internal teams, key customers, and strategic partners.
  • Conduct competitive and market analyses to identify emerging trends, customer needs, and technology shifts, including total cost of ownership compared with competing analytical methods and companies.
  • Translate market and customer insights into strategies and market requirements for product development, positioning, and messaging.
  • Work with regional teams to capture customer feedback and prioritise solution enhancements.
  • Collaborate with Product Management, R&D, Marketing, Sales, and Service teams to ensure portfolio coherence and strategic alignment.
  • Develop and drive go-to-market initiatives by providing value propositions, persona definitions, competitive solution positioning, training, and sales materials.
  • Act as the portfolio’s business owner, balancing technical innovation with commercial viability.
Desired Qualifications
  • An MBA or equivalent business qualification is a strong advantage.
  • Experience using NMR and/or EPR is optional.
  • Experience in analytical instrumentation, life sciences, cleantech, or industrial markets is preferred.

About the company

Bruker makes analytical and diagnostic instruments used by researchers and industries. Its products help analyze materials and biological samples to reveal chemical structure, composition, and properties, with notable roots in nuclear magnetic resonance (NMR) technology and a broad portfolio beyond that field. The company works by designing and selling instruments such as analytical tools that collect data from samples (for example, signals from nuclei in NMR or other spectroscopic methods) and provide insights to researchers. Bruker differentiates itself through a long history of developing advanced technologies, a focus on innovation in scientific instrumentation, and a global product range serving life sciences, materials science, and environmental analysis, supported by steady investment in research and development. Its goal is to equip researchers and industries with reliable tools to push the boundaries of what is possible in science and discovery.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Billerica, Massachusetts

Founded

1960

Get referred to Bruker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 timsUltra AIP and timsOmni launches deepen proteomics and oligonucleotide workflows.
  • August 10, 2026 MIMETAS deal expands Bruker into human-relevant drug discovery models.
  • UC Berkeley ordered over $6 million of Bruker NMR systems, delivering 2027 revenue.

What critics are saying

  • Bruker’s first-half 2026 organic revenue declined 0.8%, exposing fragile demand recovery.
  • Academic spending stayed soft in 2026, while tariffs and currency pressured results.
  • If MIMETAS and fusion remain niche, Bruker’s acquisition-heavy strategy destroys capital returns.

What makes Bruker unique

  • Bruker owns timsTOF proteomics, NMR, microscopy, and microphysiological systems under one platform.
  • Bruker’s August 31 XFlash 7200 FIRE raises SEM-EDS throughput beyond conventional detector designs.
  • Bruker’s BEST superconductors supply ITER, Wendelstein 7-X, CERN, and fusion demonstrators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Life Insurance

Dental Insurance

Flexible Work Hours

Employee Discounts

Growth & Insights and Company News

Headcount

6 month growth

13%

1 year growth

13%

2 year growth

13%
Business Wire
Oct 14th, 2026
Bruker Completes Acquisition of PhenomeX

Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools...

Financial Times
Sep 28th, 2026
Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research.

Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research. Sep 28 2026 12:00 BST * MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP * ProteoScape connects PASEF discovery with rapid prm-PASEF target validation * Spectronaut(R) AI transfer learning accelerates adaptation to new MS capabilities * Guided PASEF EXciD enables high-throughput glycopeptide characterization * Integrated HDX-MS workflows advance protein conformation and interaction studies * timsOmni(TM) enables RNA and DNA top-down structural and native RNA analysis SINGAPORE-(BUSINESS WIRE)-Sep. 28, 2026- At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF discovery with prm-PASEF target validation on the same timsTOF platform. Novel timsOmni and integrated HDX-MS workflows extend structural analysis to glycopeptides, proteins, and nucleic acids.

MarketScreener
Sep 21st, 2026
Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure.

Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure. Published on 09/21/2026 at 09:36 am EDT S&P Capital IQ Bruker Corporation announced a multi-system order from University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz?class instrumentation. The investment is centered on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by several additional NMR systems and upgrades supporting solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research. The UC Berkeley NMR order exceeds USD 6 million and is expected to be delivered in 2027. (C) S&P Capital IQ - 2026

U.S. Securities and Exchange Commission
Sep 19th, 2026
10-K

Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

U.S. Securities and Exchange Commission
Sep 18th, 2026
10-Q

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023